Giant cell arteritis (GCA), the most common primary vasculitis in adults, is a granulomatous
systemic vasculitis usually affecting the aorta and its major branches, particularly the carotid …

Interleukin-6 inhibitors appear efficacious in the treatment of refractory cases of LVV;
however, utility in newly diagnosed immunosuppressive-naïve patients is less well …

Purpose Management of giant cell arteritis (GCA, Horton's disease) involves many
uncertainties. This work was undertaken to establish French recommendations for GCA …

Background Placebo-controlled clinical trials have demonstrated the efficacy of tocilizumab
(TCZ) for remission maintenance and glucocorticoid sparing in patients with giant cell …

Overview. The GiACTA trial is a multicenter, randomized, double‐blind, and placebo‐
controlled study designed to test the ability of tocilizumab (TCZ), an interleukin (IL)‐6 …

Giant cell arteritis (GCA) is the most common idiopathic systemic vasculitis in persons aged
50 years or greater. Treatment options for GCA, to-date, have been limited and have …

Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are large vessel vasculitis (LVV) and
aortic involvement is not uncommon in Behcet's disease (BD) and relapsing polychondritis …

Research into giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) has become
more important in the last few decades. Physicians are facing several challenges in …

GCA shares many clinical features with PMR and Takayasu arteritis. The current mainstay of
therapy for all three conditions is glucocorticoid therapy. Given the chronic, relapsing nature …

Giant cell arteritis (GCA) is a medium-to-large vessel vasculitis with potentially sight-and life-
threatening complications. Our understanding of the pathogenesis, diagnosis, and treatment …